GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise Against Variants
GeoVax Labs, Inc. reports preclinical success of its multi-antigen COVID-19 vaccines, GEO-CM04S1 and GEO-CM02, in providing durable, cross-reactive immunity against SARS-CoV-2 variants, including Omicron XBB.1.5, highlighting the potential for broader protection without the need for frequent updates.
GeoVax Labs, Inc. has presented findings at the Keystone Symposia demonstrating the efficacy of its multi-antigen COVID-19 vaccine candidates, GEO-CM04S1 and GEO-CM02, against various SARS-CoV-2 variants, including Omicron XBB.1.5. The studies, presented by Drs. Pratima Kumari and Amany Elsharkawy, showcase the vaccines' ability to induce durable, cross-reactive immunity in preclinical animal models, suggesting a significant advancement in addressing variant evasion and enhancing immune response in vulnerable populations.
Key findings from the GEO-CM02 study revealed that a single dose provided complete protection against the original Wuhan strain and the Omicron BA.1 variant in hACE2 mouse models. Two-dose regimens further enhanced immune memory, reducing viral loads and inflammatory markers. The GEO-CM04S1 study demonstrated full protection against clinical disease and lung injury in mice challenged with the original B.1 strain or the Omicron XBB.1.5 subvariant, even in the absence of detectable neutralizing antibodies against XBB.1.5, indicating the role of T-cell mediated immunity.
Mark Newman, PhD, Chief Scientific Officer of GeoVax, emphasized the importance of inducing broadly specific immune responses to protect against evolving SARS-CoV-2 variants. The multi-antigen design strategy of GeoVax's vaccines could reduce the need for frequent updates to COVID-19 vaccines and yearly booster doses, offering a more sustainable solution to pandemic preparedness and public health resilience.
GeoVax's MVA vaccine platform, with lead candidate GEO-CM04S1 currently in multiple Phase 2 clinical trials, represents a promising approach to overcoming the challenges posed by rapidly mutating viruses. The ability of these vaccines to provide cross-protective immunity without the reliance on neutralizing antibodies opens new avenues for vaccine development, particularly for immunocompromised individuals and those with suboptimal responses to current vaccines.